MS patients with Medicare plans that exclude more drugs have a higher risk of relapse They might not be able to afford the drugs that would work best for them TUESDAY, Aug. 5, 2025 (HealthDay News) — ...

Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive disease-modifying drugs, a new study has found. Uncertainty about the impact of these drugs during pregnancy ...

Quantum BioPharma Ltd. announced the completion of dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302 (Lucid-MS), aimed at treating Multiple Sclerosis (MS). This ...

Even women with more severe MS cases are less likely than men to get critical treatments, a new study finds. Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive ...

Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and autoimmune diseases. New research from the USC Schaeffer Center shows how ...

Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and autoimmune diseases. New research from the USC Schaeffer Center shows how ...

Following successful small-animal trials that confirmed bioequivalence, BioNxt is now taking the final preclinical step to prepare its sublingual Cladribine formulation for human testing. The upcoming ...

BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...

Serena Hostvet has trouble keeping her hand steady when drawing something simple like a pumpkin, and it infuriates her. “At this point, I would just give up,” said Hostvet, 43, of Eau Claire, ...